Status:
COMPLETED
Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
SARS-CoV-2 Serological Status
SARS-CoV-2 Seroprevalence
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
COVID-19 is a new emerging disease caused by infection with the SARS-CoV-2 coronavirus, with no specific therapeutic options. Since the end of February 2020, the Strasbourg University Hospital (HUS) ...
Eligibility Criteria
Inclusion
- Any person, male or female, over 18 years of age at the time of signing the consent
- Any person affiliated to a social health insurance scheme
- Any person able to understand the objectives and risks related to research and to give an informed, dated and signed consent
- Any person who is part of HUS staff and working at HUS at the time of the pandemic, including residents affiliated with HUS and assigned to general hospitals in the region
- Any symptomatic person with a positive COVID result (PCR + group) or negative (PCR- group) with a RT-PCR test carried out at least 10 days before inclusion, or any person, for which no COVID PCR was performed (group " No PCR")
Exclusion
- Person in exclusion period (determined by a previous or ongoing study),
- Inability to give clear information (person in an emergency, difficulty understanding the subject, etc.)
- Person under safeguard of justice
- Person under guardianship or curatorship
Key Trial Info
Start Date :
April 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 16 2021
Estimated Enrollment :
1466 Patients enrolled
Trial Details
Trial ID
NCT04441684
Start Date
April 17 2020
End Date
July 16 2021
Last Update
July 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpitaux Universitaires de Strasbourg - Centre d'Investigation Clinique - Nouvel Hôpital Civil et Hautepierre
Strasbourg, France